Oncology Institute (TOI) CEO logs tax-related restructuring of 23,058 shares

Rhea-AI Filing Summary

Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative equity transaction involving 23,058 shares of common stock. According to the footnote, the issuer executed a sale of these shares to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award made on May 21, 2024.

Following this tax-related transaction, Virnich directly holds 2,337,166 shares of common stock. The filing does not show any open-market buying or selling by him, but rather a routine step connected to equity compensation and associated taxes.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Virnich Daniel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Other	Common Stock	23,058	$4.47	$103K

Holdings After Transaction: Common Stock — 2,337,166 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares in transaction: 23,058 shares Transaction price: $4.47 per share Post-transaction holdings: 2,337,166 shares

3 metrics

Shares in transaction 23,058 shares Common stock involved in tax-related transaction on May 21, 2026

Transaction price $4.47 per share Price per share for common stock in the reported event

Post-transaction holdings 2,337,166 shares Common stock directly held by CEO after the transaction

Key Terms

RSU award, sale to cover, other acquisition or disposition

3 terms

RSU award financial

"the vesting of an RSU award made on May 21, 2024"

sale to cover financial

"executed the sale to cover the tax liabilities arising from the vesting"

other acquisition or disposition financial

"transaction_code_description": "Other acquisition or disposition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Virnich Daniel

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		J(1)		23,058	D	$4.47	2,337,166	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer executed the sale to cover the tax liabilities arising from the vesting of an RSU award made on May 21, 2024.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TOI CEO Daniel Virnich report on this Form 4?

Daniel Virnich reported an administrative equity transaction involving 23,058 shares of Oncology Institute common stock. A footnote explains the issuer executed a sale to cover tax liabilities tied to an RSU award vesting on May 21, 2024.

Was the TOI CEO’s Form 4 transaction an open-market buy or sell?

The Form 4 does not report an open-market buy or sell by the CEO. Instead, it describes a sale executed by the issuer to cover tax liabilities from an RSU vesting, categorized as an “other” transaction event.

How many TOI shares were involved in the CEO’s tax-related transaction?

The transaction involved 23,058 shares of Oncology Institute common stock. These shares were sold by the issuer at $4.47 per share specifically to satisfy tax obligations triggered by the vesting of a prior RSU award.

What is Daniel Virnich’s TOI shareholding after this Form 4 transaction?

After the reported transaction, Daniel Virnich directly holds 2,337,166 shares of Oncology Institute common stock. This total reflects his position following the tax-related sale executed in connection with the vesting of a restricted stock unit award.

How is the TOI CEO’s Form 4 transaction classified in the filing data?

The transaction is coded “J” and labeled as an “other acquisition or disposition” of non-derivative common stock. Summary data classifies it as a restructuring-type event, not a standard buy, sell, gift, or tax-withholding code.